続発性副腎機能不全:治療薬市場動向2014(市場規模、グローバルAPIメーカー、第Ⅲ相試験)

◆英語タイトル: Secondary Adrenal Insufficiency Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
◆商品コード:DIIR2014460
◆発行会社(調査会社):DelveInsight
◆発行日:2014年版(※最新版はお問い合わせください)
◆ページ数:75以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。



【レポートの概要】

DelveInsight’s, “ Secondary Adrenal Insufficiency- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


• A snapshot of the global Market therapeutics scenario for Secondary Adrenal Insufficiency.
• A review of the marketed products under prescription for Secondary Adrenal Insufficiency, regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Secondary Adrenal Insufficiency with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Secondary Adrenal Insufficiency drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Secondary Adrenal Insufficiency drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Secondary Adrenal Insufficiency drugs.
• Coverage of Secondary Adrenal Insufficiency Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure from 2011-2015.

• Evaluate the marketing status and exclusivity details of Secondary Adrenal Insufficiency key products to exploit opportunities for generic drug development opportunities.
• Identify and understand important and diverse types of therapeutics under Phase III development for Secondary Adrenal Insufficiency.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Secondary Adrenal Insufficiency.
• API intelligence over marketed drugs for Secondary Adrenal Insufficiency and gaining primary intelligence over active ingredients manufacturers across the globe.
• API intelligence over leading Phase III pipeline drugs.
• Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
• Understanding the scope of the Phase III Drugs with nil regulatory filings.
• Understanding the chemical route of synthesis of approved drugs for Secondary Adrenal Insufficiency.
• Uncovering opportunities in the rapidly growing the US markets.

【レポートの目次】

• Indication Overview
• Marketed Drugs Assessment
• Marketed Details of Drugs by Application Type
• Marketed Details of Drugs (NDA) by Marketing Status
• Marketed Details of Drugs by Patent Expiration Timeline
• The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
• The API Manufacturers by the United States Drug Master File (US DMF) Status
• The API Manufacturers by the US DMF Status (Drug Specific)
• The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
• The API Manufacturers by the US DMF Status (Drug Specific)
• Drugs Market Data and Forecasted Sales Figures (2011-2015)
• Marketed Drugs Information
• Drugs Description
• Route of Synthesis
• Global Active Pharmaceutical Manufacturers
• Approval Status
• Patent and Exclusivity Details
• Company Overview
• Phase III Drugs Information
• Phase III Drugs Description
• The United States Drug Master Filings (US DMF)
• Discontinued Drugs Information

Secondary Adrenal Insufficiency Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Secondary Adrenal Insufficiency Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Secondary Adrenal Insufficiency Therapeutic Market, US, (Year), 2014
Secondary Adrenal Insufficiency Marketed Drugs, API Manufacturers by US DMF Status, 2014
Secondary Adrenal Insufficiency Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Secondary Adrenal Insufficiency Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Secondary Adrenal Insufficiency Therapeutic Market, Global Sales (in million USD), 2014
Secondary Adrenal Insufficiency Marketed Drugs, API Manufacturers, Global, 2014
Secondary Adrenal Insufficiency Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Secondary Adrenal Insufficiency, 2014

Secondary Adrenal Insufficiency Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Secondary Adrenal Insufficiency Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Secondary Adrenal Insufficiency Therapeutic Market, US, (Year), 2014
Secondary Adrenal Insufficiency Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Secondary Adrenal Insufficiency Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Secondary Adrenal Insufficiency Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Secondary Adrenal Insufficiency Therapeutic Market, Global Sales (in million USD), 2014
Secondary Adrenal Insufficiency Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

【掲載企業】

Pfizer Inc.
Merck & Co., Inc.
Schering-Plough Corporation (Inactive)

【レポートのキーワード】

Secondary Adrenal Insufficiency、医薬品、治療薬、規模、販売量、医薬品有効成分(API)メーカー、第Ⅲ相試験、製薬

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[続発性副腎機能不全:治療薬市場動向2014(市場規模、グローバルAPIメーカー、第Ⅲ相試験)]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。H&I文字はH&Iグローバルリサーチ株式会社の商標(登録第5783645号)です。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。
※当サイトでは2016年05月25日現在 190,338 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆